Key facts
- Sonic Incytes’s last known valuation is $80.0M (Oct 2025).
- It has raised $39.4M; the latest was Later Stage VC ($25.0M) in Oct 2025.
- Notable investors include Creative Destruction Lab, Mana Ventures, MedTech Innovator, Gaingels, Life Sciences BC — 27 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Sonic Incytes
- ·The full record, as it builds
Funding rounds
No funding rounds for Sonic Incytes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sonic Incytes
Developer of an AI-guided ultrasound elastography device designed to assess and monitor chronic liver diseases at the point of care. The company's devices utilize artificial intelligence to offer deeper measurements and larger tissue samples, single probes without recalibrations, and guidance to check for liver stiffness, attenuation, and velacur-determined fat fraction, enabling healthcare providers to perform non-invasive liver assessments efficiently and support accurate clinical decision making during patient visits.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2016
- Employees
- 41
- Website
- sonicincytes.com/
- Ownership
- Privately Held (backing)
Sonic Incytes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sonic Incytes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sonic Incytes in its N-PORT filings yet. We sweep new filings monthly.